The Filing Desk

MeiraGTx

MGTX · Nasdaq · Health Care · Financials, fiscal 2017 to 2025

MGTX · Last close · November 13, 2026
$9.18
Value MeiraGTx yourself

MeiraGTx's revenue rose 144.6% to $81 million in fiscal 2025. Its operating margin was −130.2%, up from −493.4% a year earlier. Free cash flow was −$50 million. The diluted share count rose 15.2%.

MeiraGTx Holdings plc Latest fiscal year ended December 31, 2025 10-K filed March 30, 2026 · 0001104659-26-036494 Updated
Revenue
$81M
144.6%
Operating margin
−130.2%
363.2 pts
Net income
−$114M
 
Free cash flow
−$50M
 
Return on equity
−368.2%
224.7 pts
Market cap
$890M
Nov 13 close
P/E
11.5x
On $0.80 EPS, 4 qtrs

Operating margin is operating income as a share of revenue. Free cash flow is cash from operations minus capital spending. Return on equity is net income as a share of shareholders' equity. Market cap is the last closing share price times the latest diluted share count, so it is approximate. P/E is the last close divided by diluted earnings per share over the last four quarters, or the latest fiscal year where the quarters aren't available; there is none when the company made a loss.

About these figures. Return on capital for fiscal 2025 is blank: invested capital is small next to total assets (cash nearly matches equity and debt), so the ratio isn't meaningful.

Charts show fiscal years, from the 10-K filings.

What MeiraGTx does

MeiraGTx is a clinical-stage genetic medicines company, meaning its medicines are still being tested in people. Its programs give small doses of genetic medicine directly to the affected part of the body. Late-stage programs include dry mouth caused by radiation treatment, Parkinson's disease and an inherited eye disease linked to the AIPL1 gene.

It makes its own medicines. It owns two viral vector factories, in London and Shannon, Ireland, plus its own plasmid production and quality control. A viral vector is a harmless virus used to carry genes into cells. In December 2025 UK regulators gave its London plant a commercial manufacturing authorization. It supplies product to others under supply agreements.

MeiraGTx also developed a gene-control technology, built on molecules called riboswitches, that lets an oral small-molecule pill turn a gene's output up or down. It is applying this to metabolic hormones such as GLP-1, to cell therapy and to chronic pain. It has sold a program under an asset purchase agreement that could bring milestone payments, and it is reviewing strategic transactions.

Its biggest risks, as it describes them

  • It has lost money since it started and may never be profitable.
  • It may not receive the milestone payments or commercial supply revenue it expects from an asset sale and supply agreement.
  • It needs additional capital, and may struggle to meet debt obligations and covenants.
  • It depends on the success of product candidates still in development.
  • Gene therapy is new, so the rules and the time and cost to win approval are uncertain.
From MeiraGTx's annual report on Form 10-K, filed March 30, 2026, in our words; the 10-K has the full description and every risk factor. Updated with each new annual report.

Income statement

Revenue and net income
US$ billions, fiscal years; net losses in red. Revenue on the left axis, net income on the right; zero is the same line on both.
Revenue (left axis)Net income (right axis)
Gross profit, R&D and operating income
US$ billions, fiscal years. Gross profit is revenue minus the cost of what was sold; research and development is one of the costs paid from it; what remains after all operating costs is operating income. Losses in red.
Gross profitResearch and developmentOperating income
Margins
Percent of revenue
GrossOperatingNetFree cash flow

MeiraGTx lost money in fiscal 2025: a net loss of $114 million.

Diluted earnings per share
US$ per share, fiscal years, restated for any stock splits; loss years in red.

Returns on capital

Return on capital and on equity
Percent. Return on capital is after-tax operating income over the money invested in the business (debt plus equity, minus cash); return on equity is net income over shareholders' equity. Both use the average of opening and closing balances.
Return on capitalReturn on equity

Balance sheet

Cash and debt
US$ billions, at each fiscal year end. Debt includes finance leases.
Cash and short-term investmentsDebt
Assets, liabilities and equity
US$ billions, at each fiscal year end. Assets equal liabilities plus equity; negative equity in red.
Total assetsTotal liabilitiesShareholders' equity
Debt and liquidity ratios
Times. Debt to equity, current assets over current liabilities, and net debt over EBITDA (a full year's).
Debt to equityCurrent ratioNet debt to EBITDA

Five years at a glance

Fiscal year endFY21FY22FY23FY24FY25
Cash and short-term investments13811613010466
Debt incl. finance leases—71727374
Net debt (negative means net cash)—−44−58−309
Net debt to EBITDA—————
Debt to equity—0.6x0.5x1.1x—
Interest coverage−252.6x−23.5x−10.3x−12.4x−8.7x
Current ratio2.7x1.9x2.4x2.0x0.8x
Quick ratio2.7x1.9x2.4x2.0x0.8x
US$ millions unless stated, at each fiscal year end. Net debt to EBITDA is debt minus cash, divided by operating income before depreciation and amortization: roughly how many years of those earnings the net debt equals. Debt to equity is debt as a multiple of shareholders' equity. Interest coverage is operating income divided by interest expense. The current ratio is current assets over current liabilities; the quick ratio leaves out inventory.

Cash flow

Cash from operations, capital spending and free cash flow
US$ billions, fiscal years. Free cash flow is cash from operations minus capital spending; negative years in red.
Cash from operationsCapital spendingFree cash flow
Stock-based compensation and buybacks
US$ billions, fiscal years. Shares paid to employees (stock-based compensation, a cost that uses no cash) against cash spent buying shares back. Buybacks that only match it leave the share count roughly where it was.
Stock-based compensationShare buybacks
Dividends and buybacks
US$ billions, cash paid in each fiscal year
DividendsShare buybacks
Diluted share count
Weighted-average diluted shares, millions

Projections

Project MeiraGTx's revenue, net income and earnings per share five years ahead in a bull, a base and a bear case with your own figures, and see the share prices your P/E estimates give them, or value it with a discounted cash flow model. Every projected figure is yours: it is not a forecast of ours.

Insider trades

No officer, director or 10% owner of MeiraGTx reported buying or selling its shares on the open market between November 14, 2025 and November 13, 2026.

From Form 4 filings with the SEC. Grants, option exercises and shares withheld for tax aren't counted. Insider trades at all companies

Indicators

Four widely used measures, worked out from the company's filings. The cutoffs are the ones their authors or users go by, not a verdict of ours.

IndicatorFY23FY24FY25
Piotroski F-score2 of 82 of 83 of 8
Rule of 40−907.6%−191.5%82.9%
Altman Z''−5.72−10.70−14.65
Accruals ratio6.6%−14.5%−26.4%
Piotroski F-score: how many of nine simple tests of profitability, funding and efficiency the company passed in the year (Piotroski, 2000); 8 or 9 is strong, 0 to 2 weak. Rule of 40: revenue growth plus free cash flow margin; software investors treat 40% or more as the bar. Altman Z'': working capital, retained earnings, operating income and equity weighed against assets and liabilities (Altman, 1995); Altman puts above 2.6 in the safe zone and below 1.1 in the distress zone. Accruals ratio: net income minus cash from operations, over average total assets; lower means profit is backed by cash.

The nine F-score tests

TestFY23FY24FY25
Net income is positiveFailFailFail
Cash from operations is positiveFailFailFail
Return on assets rosePassFailPass
Cash from operations exceeds net incomeFailPassPass
Debt fell relative to assetsFailFailFail
Current ratio rosePassFailFail
Share count didn't riseFailFailFail
Gross margin rose———
Revenue rose relative to assetsFailPassPass
F-score2 of 82 of 83 of 8
Companies that report no gross profit are scored on the other eight.

Compare

Put MeiraGTx side by side with any other company we cover: revenue, growth, margins, cash flow and returns, with ten years of charts.

Similar companies

CompanyYearRevenue growthOperating marginFree cash flow marginReturn on capitalNet debt to EBITDAF-scoreCompare
MeiraGTxFY25144.6%−130.2%−61.7%——3
4D Molecular TherapeuticsFY25230,194.6%−187.2%−128.7%———Compare
CytomX TherapeuticsFY25−44.8%−29.4%−99.5%———Compare
CytokineticsFY25376.6%−695.4%−607.5%———Compare
Recursion PharmaceuticalsFY2526.9%−867.9%−506.5%−117.2%—4Compare
Each company's latest fiscal year. Fiscal years end in different months, so the periods don't line up exactly. Free cash flow margin is free cash flow as a share of revenue. Net debt to EBITDA is explained under the balance sheet, and the F-score under Indicators.

9 years of figures

Fiscal yearFY17FY18FY19FY20FY21FY22FY23FY24FY25
Income statement
Revenue——13163816143381
Revenue growth———17.1%142.2%−57.8%−11.9%137.4%144.6%
Gross profit—————————
Research and development223425346786104120130
Operating income−32−78−58−63−73−116−137−164−106
Net income−31−83−55−58−80−130−84−148−114
Diluted EPS (US$)−3.72−4.47−1.65−1.54−1.80−2.87−1.49−2.12−1.42
Diluted shares (millions)91933384445567080
Cash flow
Cash from operations−18−5920−64−10−73−105−104−46
Capital expenditure101192146452054
Free cash flow−29−7011−85−57−118−126−109−50
Dividends paid000000000
Share buybacks000000000
Acquisitions000000000
Stock-based compensation31816182129282522
Balance sheet at fiscal year end
Cash and short-term investments86822721013811613010466
Debt incl. finance leases—————71727374
Total assets2697324364320318327270244
Total liabilities2216133125135200189202250
Shareholders' equity−478119123918511813868−6
Margins and ratios
Gross margin—————————
Operating margin——−438.4%−401.9%−193.0%−730.9%−977.8%−493.4%−130.2%
Net margin——−411.9%−372.6%−211.0%−814.2%−599.5%−444.1%−140.3%
Free cash flow margin——83.2%−545.5%−150.9%−741.6%−895.6%−328.9%−61.7%
Rule of 40 (growth + FCF margin)———−528.4%−8.6%−799.4%−907.6%−191.5%82.9%
Return on capital——————−140.6%−219.7%—
Return on equity—−491.9%−40.3%−27.0%−37.5%−85.5%−65.7%−143.5%−368.2%
Return on assets—−135.0%−26.0%−16.9%−23.3%−40.6%−26.1%−49.5%−44.4%
Net debt to EBITDA—————————
US$ millions unless stated. Where a later 10-K restated a year, the latest filed figure is shown. Download all figures (CSV, US$ millions)
Source: MeiraGTx's Form 10-K filings, from SEC EDGAR. For information only, not investment advice. The Filing Desk is not affiliated with MeiraGTx.